- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: CGP-48933 | Diovan® | Prexxartan® (oral solution)
valsartan is an approved drug (FDA (2012))
Compound class: Synthetic organic
Comment: Valsartan is an antagonist with high affinity for the type I (AT1) angiotensin receptor.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
View more information in the IUPHAR Pharmacology Education Project: valsartan
|No information available.|
|Summary of Clinical Use|
|Used as a single agent in the treatment of various cardiovascular conditions including hypertension, heart failure and diabetic nephropathy.
Fixed-dose combination drugs
Entresto®, a combination with sacubitril (a neprilysin inhibitor) is approved for heart failure.
Byvalson®, a combination drug containing nebivolol (5mg; a β1-adrenoceptor antagonist) and valsartan (80mg) was approved by the FDA in June 2016 for the treatment of hypertension.
|Mechanism Of Action and Pharmacodynamic Effects|
|Inhibits the binding of angiotensin II to the AT1 receptor (AGTR1), thereby inhibiting the AT1-mediated vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to a decrease in vascular resistance and blood pressure.|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)